By Jared S. Hopkins
Abbott Laboratories forecasts an impact of "a few hundred million dollars" this year from Trump administration tariffs, Chief Executive Robert Ford told analysts Wednesday.
The healthcare company sees the costs starting in the third quarter. Ford told analysts it is too early to simply double the 2025 estimate for how tariffs might affect Abbott in future years, but the company can cover them in the near term.
Illinois-based Abbott's products include baby formula and medical devices, with some devices imported from overseas. The company is studying how to mitigate tariffs long term, and expects its global manufacturing network to help with those efforts, Ford said.
"One thing we have learned from tariffs is they don't go away, so whatever comes it stays, and it stays for a while," he said. "Look at the tariffs that went in place in 2017. They're still there."
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
April 16, 2025 11:19 ET (15:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.